IN
INGN.US Inogen Inc
- Market cap
- USD 148M
- P/E
- -
- P/B
- 0.94x
- ROE
- -24.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INGN.US undervalued?
Graham numberThe Graham number of Inogen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inogen Inc fundamental analysis
No fundamental analysis for Inogen Inc yet.
Inogen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5…
Full company profileInogen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inogen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 203M | 249M | 358M | 362M | 308M | 358M | 377M | 316M | 336M | 349M | 343M |
| Gross Profit | 97.3M | 121M | 179M | 172M | 138M | 176M | 154M | 127M | 155M | 166M | 159M |
| Operating Income | 22.9M | 27.6M | 37.9M | 19.8M | -12.0M | 9.24M | -85.2M | -109M | -42.5M | -30.2M | -38.8M |
| EBITDA | 36.4M | 39.9M | 49.2M | 33.6M | 6.56M | 30.3M | -9.57M | -58.3M | -15.5M | -2.72M | -23.4M |
| Net Income | 20.5M | 21.0M | 51.8M | 21.0M | -5.83M | -6.33M | -83.8M | -102M | -35.9M | -22.7M | -37.8M |
| EPS | 0.97 | 0.96 | 2.30 | 0.94 | -0.27 | -0.28 | -3.67 | -4.42 | -1.52 | -0.84 | -1.43 |
| Balance Sheet | |||||||||||
| Total Assets | 214M | 275M | 376M | 447M | 462M | 490M | 405M | 326M | 296M | 299M | 265M |
| Total Liabilities | 32.0M | 48.0M | 65.5M | 103M | 112M | 119M | 108M | 121M | 122M | 106M | 108M |
| Shareholders' Equity | 182M | 227M | 310M | 345M | 350M | 370M | 297M | 205M | 174M | 192M | 157M |
| Cash & Short-term Investments | 114M | 174M | 240M | 209M | 231M | 246M | 187M | 128M | 114M | 120M | 96.8M |
| Total Debt | - | - | - | 6.72M | 10.0M | 26.7M | 23.3M | 21.9M | 19.4M | 17.5M | 14.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 31.0M | 60.5M | 60.0M | 40.6M | 37.0M | 23.6M | -37.5M | -3.23M | 5.91M | -11.2M | -10.9M |
| Capital Expenditure | 8.02M | 10.2M | 13.0M | 6.51M | 17.3M | 23.9M | 21.2M | 26.5M | 17.1M | 10.4M | 5.60M |
| Free Cash Flow | 23.0M | 50.3M | 47.0M | 34.1M | 19.7M | -302K | -58.8M | -29.8M | -11.2M | -21.6M | -12.5M |
| Ratios | |||||||||||
| ROE | 11.3% | 9.3% | 16.7% | 6.1% | -1.7% | -1.7% | -28.2% | -50.0% | -20.6% | -11.8% | -24.1% |
| ROA | 9.6% | 7.6% | 13.8% | 4.7% | -1.3% | -1.3% | -20.7% | -31.4% | -12.1% | -7.6% | -14.3% |
| Net Profit Margin | 10.1% | 8.4% | 14.5% | 5.8% | -1.9% | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% | -11.0% |
| Debt to Equity | - | - | - | 0.02x | 0.03x | 0.07x | 0.08x | 0.11x | 0.11x | 0.09x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inogen Inc dividends
Inogen Inc has not paid dividends in the last 9 fiscal years.
Who owns Inogen Inc
- Insiders 13.95%
- Institutions 81.68%
- Public & others 4.37%
- Shares outstanding 26.0M
- Free float 22.6M
Top funds holding INGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 740K | 2.85% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 629K | 2.42% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 371K | 1.43% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 242K | 0.93% | -9.61% | Aug 2026 |
| iShares Russell 2000 Value ETF | 219K | 0.84% | 0.00% | Oct 2026 |
| JPMorgan Small Cap Value I | 217K | 0.83% | -2.06% | Sep 2026 |
| Bridgeway Ultra-Small Company | 156K | 0.60% | +23.89% | Jun 2026 |
| Vanguard Russell 2000 ETF | 143K | 0.55% | +0.91% | Sep 2026 |
| DFA U.S. Small Cap I | 121K | 0.46% | 0.00% | Sep 2026 |
| Federated Hermes MDT Small Cap Core ETF | 117K | 0.45% | +6.96% | Oct 2026 |
| PV BUYBACK USA Classe B USD | 112K | 0.43% | 0.00% | Jun 2026 |
| CREF Total Global Stock Account R3 | 111K | 0.43% | -4.96% | Sep 2026 |
| Fidelity Extended Market Index | 110K | 0.42% | +14.50% | Sep 2026 |
| JPMorgan US Small Company L | 96.9K | 0.37% | 0.00% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 88.6K | 0.34% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 84.6K | 0.33% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 74.1K | 0.28% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 64.8K | 0.25% | +12.50% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 63.7K | 0.25% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 60.9K | 0.23% | -5.91% | Oct 2026 |
Top institutions holding INGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 1.75M | 6.73% | +6.19% | Jun 2026 |
| Acadian Asset Management LLC | 1.10M | 4.22% | 0.00% | Sep 2026 |
| Armistice Capital, LLC | 1.10M | 4.22% | -8.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.04M | 3.99% | +0.16% | Jun 2026 |
| Ameriprise Financial Inc | 983K | 3.78% | +14.37% | Jun 2026 |
| AQR Capital Management LLC | 937K | 3.60% | +119.46% | Jun 2026 |
| Dafna Capital Management LLC | 845K | 3.25% | 0.00% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 743K | 2.86% | +26.80% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 646K | 2.49% | +19.42% | Jun 2026 |
| Geode Capital Management, LLC | 642K | 2.47% | +4.56% | Jun 2026 |
| State Street Corp | 592K | 2.28% | +3.27% | Jun 2026 |
| Federated Hermes Inc | 535K | 2.06% | +3.94% | Jun 2026 |
| JPMorgan Chase & Co | 480K | 1.85% | +12.31% | Jun 2026 |
| Renaissance Technologies Corp | 479K | 1.84% | +0.48% | Sep 2026 |
| Dimensional Fund Advisors, Inc. | 456K | 1.75% | -6.70% | Sep 2026 |
| The Goldman Sachs Group Inc | 436K | 1.68% | -24.91% | Jun 2026 |
| CSM Advisors, LLC | 413K | 1.59% | -0.11% | Jun 2026 |
| ExodusPoint Capital Management, LP | 394K | 1.51% | +19.18% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 389K | 1.50% | +30.92% | Jun 2026 |
| Prudential Financial Inc | 329K | 1.27% | -10.87% | Jun 2026 |
Inogen Inc company profile
- Company name
- Inogen Inc
- Ticker
- INGN.US
- Exchange
- USA Stocks
- Listed since
- Feb 14, 2014
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 753
- Fiscal year end
- December
- Address
- 500 Cummings Center, Beverly, MA, United States, 01915
- Phone
- 805 562 0500
- Website
- provider.inogen.com
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Inogen Inc management
10- Mr. Kevin P. SmithGeneral Counsel, Secretary & Executive VP of Business Development · born 1971
- Ms. Jennifer Yi BoyerExecutive VP of Enterprise Enablement & Chief Human Resources Officer · born 1975
- Mr. Andrew P. RedingPresident, CEO & Director · born 1970
- Mr. Jason A. RichardsonCFO, Executive VP & Treasurer · born 1977
- Ms. Mary WrightVP & Chief Accounting Officer · born 1987
- Mr. Naga RameswamyChief Technology Officer
- Ms. Lorna WilliamsSenior Vice President of Investor Relations
- Mr. Dominic HultonChief Marketing Officer
- Mr. Philip CorrinSenior Vice President of Operations & Supply Chain
- Dr. Krishna JhaveriChief Medical Officer